Cipla Share Price Today Down 4%; Pharma Stock Among Top Nifty Losers, After USFDA Flags Lapses At Key Partner

Cipla Share Price Today: Shares of Cipla Limited saw a sharp decline during Wednesday's intraday trading session after the United States Food and Drug Administration (USFDA) submitted an observation for Pharmathen International, a key partner of Cipla.

Cipla shares were trading 4.14% lower at Rs 1,467 per share on the BSE, with a market capitalisation of Rs 83,247.43 crore as of 11:37 am. Cipla shares had touched an intraday low of Rs 1458.90 per share and an intraday high of Rs 1530.20 per share.

Cipla Shares Decline As USFDA Flags Lapses At Pharmathen International

The USFDA has released observations at Pharmathen International. Cipla has a partnership with Pharmathen to commercialise Lanreotide in the US market. Hence, regulatory development related to the Cipla partner is likely to have impacted investor sentiment.

Key Compliance Issues Flagged By the USFDA

The US drug regulator has mentioned multiple compliance gaps at Pharmathen's facilities, including inadequate procedures to prevent contamination. USFDA has also observed weak control systems to ensure sterile conditions.

The regulator has also highlighted lapses in aseptic processing areas and compliances related issues in laboratory controls, including the absence of appropriate procedures.

The process to maintain purity and quality of drug products, storage of approved sampling plans, testing protocols, and maintenance of the manufacturing building are also under the scanner.

The USFDA observations on Pharmathen are likely to impact the progress of products being developed or supplied under a partnership with Cipla.

About Cipla-Pharmathen Partnership

Pharmathen is a Greece-based contract manufacturing organisation. Cipla has partnered with Pharmathen to commercialise tumour drug Lanreotide in the US market. The recent observation by the USFDA can hinder the supply process for the drug.

Cipla Share Price Trend

Cipla shares were trading in red on Wednesday. The stock had dipped to an intraday low of Rs 1455.00 per share. Cipla share price had dipped to its 52-week low mark of Rs 1310 per share 7 April, 2025. The stock had surged to a 52-week high mark of Rs 1,672.20 per share on 23 October, 2025. The stock has a return on equity of 18.66%. Cipla share price value has declined over 2.56% in one year. Meanwhile the stock's valuation has fallen around 4% in one month.

Disclaimer: The views and recommendations expressed are solely those of the individual analysts or entities and do not reflect the views of Goodreturns.in or Greynium Information Technologies Private Limited (together referred as "we"). We do not guarantee, endorse or take responsibility for the accuracy, completeness or reliability of any content, nor do we provide any investment advice or solicit the purchase or sale of securities. All information is provided for informational and educational purposes only and should be independently verified from licensed financial advisors before making any investment decisions.